Base
Notice2026-163562026-08-11

Foreign-Trade Zone (FTZ) 61, Notification of Proposed Production Activity; Viatris Pharmaceuticals LLC; (Medications); Vega Baja, Puerto Rico

Commerce Department, Foreign-Trade Zones Board

Document Excerpt

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Commerce Foreign-Trade Zones Board [B-100-2026] Viatris Pharmaceuticals LLC submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Vega Baja, Puerto Rico within FTZ 61. The notification conforming to the requirements of the Board's regulations ( 15 CFR 400.22 ) was received on July 30, 2026. Pursuant to 15 CFR 400.14(b) , FTZ production activity would be limited to the specific foreign-status material(s)/component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via www.trade.gov/​ftz . The proposed finished products include: ativan talbets, atorvastatin tablets, celebrex capsules; colestid tablets; Detrol capsules; Dilantin tablets and capsules; Effexor capsules; eplerenone tablets; ibrance capsules; inspra tablets; Lipitor tablets; lorbrena tablets; lorviqua tablets; lyrica capsules; Neurontin tablets and capsules; nitrostat tablets; Norvasc tablets; Pristiq tablets; vizimpro tablets; Xanax immediate release tablets; Xeljanz extended release tablets; Zithromax tablets; and zyvox tablets (duty-free). The proposed foreign-status materials/components include: amlodipine besylate active pharmaceutical ingredient (API); atorvastatin API; Ativan tablets; azithrom

Read full document on FederalRegister.gov →

Full Document

Citation: 91 FR 51658